Introduction
Multiple epidemiologic studies have identified elevated levels of blood triglycerides (TGs) or the phenotypic state of hypertriglyceridaemia (HTG) as being associated with an elevated risk of cardiovascular (CV) disease.1 Among therapies demonstrating significant reduction in TGs – beyond fibrates, niacin and statins – are marine-derived omega-3 polyunsaturated fatty acids (n-3 PUFAs); they consist principally of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Notably, the first Gruppo Italiano per lo Studio della Streptochiansi nell’Infarto (GISSI) supported a potential role of n-3 PUFAs in reducing death, non-